[摘要] 目的 通过检测弥漫细胞淋巴瘤（DLBCL）患者治疗前、后血清细胞因子白介素（IL）-6、IL-10的水平变化，探讨IL-6、IL-10的表达水平与DLBCL化疗耐药的相关性。方法 将40例确诊的DLBCL患者按对化疗的敏感性分为两组（化疗耐药组及化疗敏感组）各20例，选择同期20例健康人作为对照组，用ELISA法测定DLBCL患者各阶段及对照组血清IL-6、IL-10的水平。 结果 化疗耐药组治疗前的血清中IL-6、IL-10表达水平均明显高于化疗敏感组和对照组（均P < 0.05），治疗缓解后明显低于治疗前（P < 0.05）；DLBCL复发耐药时，患者血清中的IL-6、IL-10表达水平又高于缓解时水平（均P < 0.05）。 结论 血清中细胞因子IL-6、IL-10的表达可预测DLBCL的疗效，可能是DLBCL耐药的相关指标。摘自：本科论文www.808so.com
[关键词] 弥漫细胞淋巴瘤；细胞因子；白细胞介素-6；白细胞介素-10；细胞耐药
[] C[文章编号] 1673-7210（2012）08（c）-0154-02
Correlation between the chemotherapy resistance of diffuse large B-cell lymphoma and cytokines IL-6 and IL-10
WANG Wenxia1 WANG Bin1 LIU Xinhong2
1.Department of Hematology and Oncology, the People′s Hospital of Linqu County, Shandong Province, Linqu 262600, China; 2.Department of Radiation Oncology, the People′s Hospital of Linqu County, Shandong Province, Linqu 262600, China
[Abstract] Objective To explore the relationship between the expression of serum cytokines IL-6, IL-10 and chemotherapy resistance in patients with diffuse large B-cell lymphoma (DLBCL) by monitoring the level of serum cytokines IL-6, IL-10. Methods 40 cases which diagnosed as DLBCL were enrolled, according to the sensitivity to the chemotherapy, they were divided into two groups (chemotherapy resistant group and chemotherapy sensitive group), and 20 cases in each group, another 20 cases of healthy individuals were enrolled as the control group. The levels of serum cytokines IL-6，IL-10 at different stage in DLBCL patients and normal control group were detected by ELISA. Results The levels of serum cytokines IL-6, IL-10 in chemotherapy resistant group before therapy was all higer than chemotherapy sensitive group and control group (all P < 0.05), after the treatment, it was lower than before(P < 0.05); the levels of serum cytokines IL-6, IL-10 after the DLBCL recurrence and drug resistance were higher than the remission. Conclusion The levels ofserum IL-6, IL-10 not only can predict the chemotherapy efficacy of DLBCL but also are the drug resistance factors of DLBCL.
[Key words] Diffuse large B-cell lymphoma; Cytokines; IL-6; IL-10; Drug resistance
弥漫细胞淋巴瘤（DLBCL）是一种具有异质性的恶性肿瘤，是非霍奇金淋巴瘤（NHL）病理类型中为最常见的一种，其异质性表现在临床表现、组织学形态、分子生物学和预后等方面。尽管随着对DLBCL研究的进展及治疗方法的完善，但仍有半数以上的DLBCL病例不能治愈。研究表明多药耐药基因过度表达是其难治的主要原因，但不能完全解释清楚[1-2]。难治性标准参照参考文献[3]。目前对于细胞因子与DLBCL化疗耐药相关性的研究较少，本研究探讨DLBCL患者化疗耐药与血清细胞因子IL-6、IL-10水平的相关性。
1 资料与方法
1.1 一般资料
选取自2010年12月～2011年12月临朐县人民医院血液肿瘤科收治的40例初治的接受正规化疗、依从性好且坚持随访的DLBCL患者为研究对象，均经病理活检、免疫组织化学证实。分为化疗耐药组（化疗耐药患者，n = 20）和化疗敏感组（化疗敏感患者，n = 20），其中男22例，女18例，年龄20～76岁，中位年龄36岁。入选标准：确诊的DLBCL患者，无明显化疗禁忌症，接受正规化疗并坚持随访。排除标准：心脏疾病、慢性呼吸系统及肝肾疾病，其他疾病继发的恶性肿瘤，影响血清细胞因子IL-6、IL-10指标的其他各种疾病。另选择同期20例健康人作为对照组。两组在年龄、性别等一般资料上比较，差异无统计学意义（P > 0.05），具有可比性。源于：论文的格式要求www.808so.com
WWw.808so.com 808论文查重
DLBCL化疗耐药与细胞因子IL
更新时间：2024-04-19
作者：用户投稿
本站原创
本站原创
点赞:25626 浏览:118941